Trio become latest Symbiosis commercial additions
pharmafile | October 12, 2026 | Appointment | | CDMO, Devices, Diagnostics, Immunology, clinical trials, pharmaceutical markets
Symbiosis Pharmaceutical Services has further strengthened its commercial team with three new appointments.
Payal Roychoudhury and Joaquín Pérez Fornieles join the Business Development team supporting growth respectively in APAC and Southern Europe and Annie Shafran joins as Inside Sales Manager.
A contract development and manufacturing organisation (CDMO), Symbiosis specialises in the aseptic manufacture and fill-finish of injectable medicines for clinical trials and commercial supply.
The Stirling-based business is targetting international growth across the Southern Europe, Asia-Pacific and the Middle East territories.
Joanne Anderson, Chief Commercial Officer at Symbiosis, said: “We’re delighted to welcome Payal, Joaquín and Annie to the Symbiosis team. Payal and Joaquín will help us build relationships in priority international markets, while Annie’s new role will strengthen the support we provide from the first client enquiry. Together, they will help more drug developers access the manufacturing capacity and expertise we have invested strongly in.”
Based in Glasgow, Roychoudhurywill focus on the Asia-Pacific and the Middle East territories. Fornieles, based in Málaga, Spain, has responsibility for Southern Europe and support for other European and selected markets. Shafran, based in Manchester, joins from LGC where she was a Key Account Manager working with international clients.
The appointments follow the recent arrival of Jay Chima as Vice President, Business Development, and Jos Vergeest as Senior Business Development Director. Symbiosis’ £26 million expansion programme, has increased its aseptic manufacturing capacity for clinical and commercial supply.
Related Content
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …
Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.
By Dr. Richard Graham Industry conversations about clinical trial participation tend to focus on awareness, …
EMA selects TrialAssure anonymisation platform for clinical trial documents
TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency …
